Savient Pharmaceuticals Inc. (NASDAQ: SVNT) Downgraded by JP Morgan to Neutral
Friday, May 06, 2022 6:00 PM

Related Stories



Savient Pharmaceuticals Inc. (NASDAQ: SVNT) was downgraded to Neutral from Overweight at JP Morgan. The price target was lowered to $10 from $14.

Total revenue increased $200,000 for the first quarter of 2011, or 18 percent, to $1.3 million for the three months ended March 31, 2011, as compared with $1.1 million for the three months ended March 31, 2010. Savient ended the quarter with $268.0 million in cash and short-term investments, an increase of $203.1 million since December 31, 2010.

Shares last traded at $8.57, down 22.65 percent. SVNT has a 52-week low of $8.52 and a 52-week high of $23.46. The company has a total market cap of $0.82 billion. The price to earnings ratio of the company is -0.010, and the PEG ratio is -0.010.

Savient Pharmaceutical, Inc., a specialty biopharmaceutical company, focuses on developing KRYSTEXXA, a biologic PEGylated uricase in the United States. Savient Pharmaceuticals, Inc. was founded in 1980 and is headquartered in East Brunswick, New Jersey.
 

Sponsors

Symbol :

Advertisement

Market news:

More news


Advertisement

    Recent Estimates

AnalystFirm NameSymbolEPS Estimate
XXXXXXXXXX AEO$0.16
XXXXXXXXXX CSCO$0.32
XXXXXXXXXX EOG$0.52
ja teremtipTTG Investments GE$0.28
XXXXXXXXXX LVS$0.44
XXXXXXXXXX ISRG$2.49
XXXXXXXXXX AAPL$5.35
markinsurace guru CINF$0.36
XXXXXXXXXX AAPL$5.35
XXXXXXXXXX ISRG$2.49